Retinal detachment adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: the retina separated from the back of the eye

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,063 adverse event reports that record the MedDRA preferred term Retinal detachment. In plain words, the term means: the retina separated from the back of the eye. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 589 reports in the 12 months to June 2026 and 572 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 895 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 589 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 28.5% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

The retina separated from the back of the eye. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 87 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Retinal detachment name as a suspect product, in order of name
Drug	Class	Reports with this term
Adalimumab	Tumor necrosis factor blocker	32
Afinitor	Kinase inhibitor	28
Alteplase		28
Avastin	Vascular endothelial growth factor inhibitor	142
Avonex	Interferon beta	88
Azathioprine	Purine antimetabolite	25
Bevacizumab	Vascular endothelial growth factor inhibitor	152
Braftovi		77
Capecitabine	Nucleoside metabolic inhibitor	37
Carboplatin	Platinum-based drug	50
Cefuroxime	Cephalosporin antibacterial	67
Cefuroxime sodium	Cephalosporin antibacterial	26
Cialis	Phosphodiesterase 5 inhibitor	34
Ciprofloxacin	Fluoroquinolone antibacterial	37
Cobimetinib	Kinase inhibitor	28
Cosentyx	Interleukin-17A antagonist	34
Cyclosporine	Calcineurin inhibitor immunosuppressant	36
Cymbalta		45
Dabrafenib	Kinase inhibitor	26
Dexamethasone	Corticosteroid	49
Docetaxel	Microtubule inhibitor	38
Dupixent	Interleukin-4 receptor alpha antagonist	97
Enbrel	Tumor necrosis factor blocker	152
Eylea	Vascular endothelial growth factor inhibitor	191
Fosamax	Bisphosphonate	56
Ganciclovir	Cytomegalovirus nucleoside analog DNA polymerase inhibitor	31
Gilenya	Sphingosine 1-phosphate receptor modulator	44
Humalog	Insulin analog	193
Humira		616
Humulin 70/30	Insulin	29
Humulin N	Insulin	65
Humulin R	Insulin	47
Imbruvica	Kinase inhibitor	35
Inflectra	Tumor necrosis factor blocker	28
Infliximab	Tumor necrosis factor blocker	25
Insulin glargine	Insulin analog	47
Jetrea		64
Keytruda	Programmed death Receptor-1 blocking antibody	30
Lantus	Insulin analog	77
Lantus Solostar	Insulin analog	35
Lucentis	Vascular endothelial growth factor inhibitor	232
Lyrica		36
Mekinist	Kinase inhibitor	42
Mektovi		75
Melphalan	Alkylating drug	40
Methotrexate	Folate analog metabolic inhibitor	68
Methylprednisolone	Corticosteroid	62
Mirtazapine		31
Mounjaro	GLP-1 receptor agonist	39
Mycophenolate mofetil	Antimetabolite immunosuppressant	33
Nivolumab	Programmed death Receptor-1 blocking antibody	26
Novolog	Insulin analog	28
Oxaliplatin	Platinum-based drug	25
Ozempic	GLP-1 receptor agonist	69
Ozurdex	Corticosteroid	76
Pegasys	Interferon alpha	33
Prednisolone	Corticosteroid	113
Prednisone	Corticosteroid	119
Propranolol	beta-Adrenergic blocker	29
Ranibizumab	Vascular endothelial growth factor inhibitor	102
Rebif	Interferon beta	44
Remicade	Tumor necrosis factor blocker	50
Revlimid	Thalidomide analog	74
Ribavirin	Nucleoside analog antiviral	57
Rinvoq	Janus kinase inhibitor	140
Rituximab	CD20-directed cytolytic antibody	61
Skyrizi	Interleukin-23 antagonist	76
Tacrolimus	Calcineurin inhibitor immunosuppressant	43
Tafinlar	Kinase inhibitor	43
Tecfidera		41
Topiramate		38
Trametinib	Kinase inhibitor	28
Trastuzumab	HER2/neu receptor antagonist	32
Triamcinolone acetonide	Corticosteroid	46
Trulicity	GLP-1 receptor agonist	43
Tysabri	Integrin receptor antagonist	64
Vabysmo		27
Vedolizumab	Integrin receptor antagonist	42
Vemurafenib	Kinase inhibitor	28
Viagra	Phosphodiesterase 5 inhibitor	37
Visudyne		57
Vuity		43
Xalatan	Prostaglandin analog	39
Xarelto	Factor Xa inhibitor	38
Xeljanz	Janus kinase inhibitor	44
Xyrem	Central nervous system depressant	25
Zometa		40

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 55 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Retinal detachment name, in order of name
Class	Reports with this term
Alkylating drug	57
Angiotensin 2 receptor blocker	66
Angiotensin converting enzyme inhibitor	30
Anti-epileptic agent	25
Anti-IgE	27
Anticholinergic	32
Antimalarial	33
Antimetabolite immunosuppressant	46
Aromatase inhibitor	60
Atypical antipsychotic	37
beta-Adrenergic blocker	57
Bisphosphonate	95
Calcineurin inhibitor immunosuppressant	104
Carbonic anhydrase inhibitor	26
CD20-directed cytolytic antibody	83
Central nervous system depressant	27
Cephalosporin antibacterial	107
Corticosteroid	552
Cytomegalovirus nucleoside analog DNA polymerase inhibitor	51
Endothelin receptor antagonist	25
Factor Xa inhibitor	70
Fluoroquinolone antibacterial	77
Folate analog metabolic inhibitor	82
GLP-1 receptor agonist	215
HER2/neu receptor antagonist	76
Herpes simplex virus nucleoside analog DNA polymerase inhibitor	29
HMG-CoA reductase inhibitor	64
Insulin	157
Insulin analog	444
Integrin receptor antagonist	106
Interferon alpha	35
Interferon beta	136
Interleukin-17A antagonist	36
Interleukin-23 antagonist	80
Interleukin-4 receptor alpha antagonist	101
Janus kinase inhibitor	230
Kinase inhibitor	490
Microtubule inhibitor	50
Nonsteroidal anti-inflammatory drug	58
Nucleoside analog antiviral	57
Nucleoside metabolic inhibitor	86
P2Y12 platelet inhibitor	41
Phosphodiesterase 5 inhibitor	101
Platinum-based drug	94
Programmed death Receptor-1 blocking antibody	104
Prostaglandin analog	64
Proton pump inhibitor	33
Purine antimetabolite	31
Pyrophosphate analog DNA polymerase inhibitor	29
RANK ligand inhibitor	27
Serotonin and norepinephrine reuptake inhibitor	39
Sphingosine 1-phosphate receptor modulator	48
Thalidomide analog	78
Tumor necrosis factor blocker	314
Vascular endothelial growth factor inhibitor	841

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Retinal detachment, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Retinal detachment
Age	Reports	Share
Under 2	60	0.7%
2 to 11	62	0.7%
12 to 17	74	0.8%
18 to 44	745	8.2%
45 to 64	2,579	28.5%
65 to 74	1,318	14.5%
75 and over	751	8.3%
Age not given	3,474	38.3%

Sex of the patient in the reports that record Retinal detachment
Sex	Reports	Share
Female	4,312	47.6%
Male	3,753	41.4%
Unknown or not given	998	11%

Age and sex are as the report gives them. 44.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Retinal detachment: adverse event reports that record this term. https://reportedreactions.com/reaction/retinal-detachment/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Retinal detachment mean in an adverse event report?

In plain words: the retina separated from the back of the eye. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page